Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
507.5 SEK | -2.59% | -1.07% | -5.67% |
Mar. 05 | Camurus' New Drug Application for Acromegaly Treatment Accepted by US FDA | MT |
Mar. 05 | Camurus AB Announces FDA Acceptance of NDA Submission for Oclaiz? for Treatment of Acromegaly | CI |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Dividend / Share (DPS) - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock
- Equities
- Stock Camurus AB - Nasdaq Stockholm
- Revisions Camurus AB